|
|
| (93 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
|
| |
| '''For patient information click [[Cardiomyopathy (patient information)|here]]'''
| |
| {{Infobox_Disease | | | {{Infobox_Disease | |
| Name = {{PAGENAME}} | | | Name = {{PAGENAME}} | |
| Line 29: |
Line 27: |
| [[Cardiomyopathy medical therapy|Medical Therapy]] | [[Cardiomyopathy surgery|Surgery]] | [[Cardiomyopathy primary prevention|Primary Prevention]] | [[Cardiomyopathy secondary prevention|Secondary Prevention]] | [[Cardiomyopathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cardiomyopathy future or investigational therapies|Future or Investigational Therapies]] | | [[Cardiomyopathy medical therapy|Medical Therapy]] | [[Cardiomyopathy surgery|Surgery]] | [[Cardiomyopathy primary prevention|Primary Prevention]] | [[Cardiomyopathy secondary prevention|Secondary Prevention]] | [[Cardiomyopathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cardiomyopathy future or investigational therapies|Future or Investigational Therapies]] |
|
| |
|
| <br>
| | ==Guidelines== |
| == <b>2023 ESC Guideline Recommendations </b> <ref name="pmid37622657">{{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657 }} </ref>==
| | [[Cardiomyopathy 2023 ESC Guideline Recommendations|2023 ESC Guideline Recommendations]] | [[Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy|2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy]] |
| | |
| <br>
| |
| ===<u> Recommendations for the Provision of Service of [[Multidisciplinary]] [[Cardiomyopathy]] Teams. </u>===
| |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
| |
| |colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
| |
| |-
| |
| | bgcolor="LightGray"|1. It is recommended that all [[patients]] with [[cardiomyopathy]] and their relatives have access to multidisciplinary teams with expertise in the [[diagnosis]] and [[management]] of [[cardiomyopathies]].
| |
| |bgcolor= "LightBlue"|C
| |
| |-
| |
| | bgcolor="LightGray"|2. Timely and adequate preparation for transition of [[care]] from [[pediatric]] to [[adult]] services, including [[joint]] [[consultations]], is recommended in all [[adolescents]] with [[cardiomyopathy]].
| |
| |bgcolor= "LightBlue"|C
| |
| |}
| |
| | |
| ===<u> Recommendations for [[Diagnostic]] [[Work-up]] in [[Cardiomyopathies]]. </u>===
| |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
| |
| |colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
| |
| |-
| |
| | bgcolor="LightGray"|1. It is recommended that all [[patients]] with suspected or established [[cardiomyopathy]] undergo [[systematic]] evaluation using a multiparametric approach that includes [[clinical]] evaluation, [[pedigree]] analysis, [[ECG]], [[Holter monitoring]], [[laboratory]] tests, and [[multimodality]] [[imaging]].
| |
| |bgcolor= "LightBlue"|C
| |
| |-
| |
| | bgcolor="LightGray"|2. It is recommended that all [[patients]] with suspected [[cardiomyopathy]] undergo evaluation of [[family history]] and that a three- to four-[[generation]] [[family tree]] is created to aid in [[diagnosis]], provide clues to underlying [[etiology]], determine [[inheritance]] pattern, and identify at- [[risk]] [[relatives]]
| |
| |bgcolor= "LightBlue"|C
| |
| |}
| |
| | |
| ===<u> Recommendations for [[Laboratory Tests]] in the [[Diagnosis]] of [[Cardiomyopathies]]. </u>===
| |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
| |
| |colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
| |
| |-
| |
| | bgcolor="LightGray"|1. Routine (first-level) [[laboratory]] tests are recommended in all [[patients]] with suspected or confirmed [[cardiomyopathy]] to evaluate [[etiology]], assess [[disease]] [[severity]], and aid in detection of extra-[[cardiac]] [[manifestations]] and assessment of secondary [[organ]] [[dysfunction]].
| |
| |bgcolor= "LightBlue"|C
| |
| |}
| |
| | |
| ===<u> Recommendations for [[Echocardiographic]] [[Evaluation]] in [[Patients]] with [[Cardiomyopathies]]. </u>===
| |
| | |
| {|class="wikitable" style="width:80%"
| |
| |- | |
| |colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
| |
| |colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
| |
| |-
| |
| | bgcolor="LightGray"|1. A comprehensive evaluation of [[cardiac]] dimensions and [[LV]] and [[RV]] [[systolic]] (global and regional) and [[LV]] [[diastolic]] function is recommended in all [[patients]] with [[cardiomyopathy]] at initial evaluation, and during follow-up, to monitor [[disease]] progression and aid [[risk stratification]] and [[management]].
| |
| |bgcolor= "Turquoise"|B
| |
| |}
| |
| | |
| ===<u> Recommendations for [[Cardiac]] [[Magnetic Resonance]] Indication in [[Patients]] with [[Cardiomyopathies]]. </u>===
| |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
| |
| |colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
| |
| |-
| |
| | bgcolor="LightGray"|1. [[Contrast]]-enhanced [[CMR]] is recommended in [[patients]] with [[cardiomyopathy]] at initial evaluation.
| |
| |bgcolor= "Turquoise"|B
| |
| |}
| |
| | |
| ===<u> Recommendations for [[Computed Tomography]] and [[Nuclear Imaging]] </u>===
| |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
| |
| |colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
| |
| |-
| |
| | bgcolor="LightGray"|1. [[DPD]]/[[PYP]]/[[HMDP]] [[bone-tracer scintigraphy]] is recommended in [[patients]] with suspected [[ATTR]]-related [[cardiac]] [[amyloidosis]] to aid [[diagnosis]].
| |
| |bgcolor= "Turquoise"|B
| |
| |}
| |
| | |
| ===<u> Recommendations for [[Genetic Counselling]] and Testing in [[Cardiomyopathies]]. </u>===
| |
| | |
| {|class="wikitable" style="width:80%"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightGreen"| [[ESC #Classification of Recommendations|Class I]]
| |
| |colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
| |
| |-
| |
| | colspan="2" style="text-align:center; background:LightGray" | <b>[[Genetic Counselling]]</b>
| |
| |-
| |
| |bgcolor="LightGray"|1. [[Genetic]] [[counselling]], provided by an appropriately trained [[healthcare]] [[professional]] and including [[genetic]] education to inform decision-making and [[psychosocial support]], is recommended for [[families]] with an [[inherited]] or suspected [[inherited]] [[cardiomyopathy]], regardless of whether [[genetic testing]] is being considered.
| |
| |bgcolor= "Turquoise"|B
| |
| |-
| |
| | colspan="2" style="text-align:center; background:LightGray" | <b>Index [[Patients]]</b>
| |
| |-
| |
| | bgcolor="LightGray"|1.
| |
| |bgcolor= "Turquoise"|B
| |
| |-
| |
| | bgcolor="LightGray"|1.
| |
| |bgcolor= "Turquoise"|B
| |
| |-
| |
| | colspan="2" style="text-align:center; background:LightGray" | <b>[[Family Members]]</b>
| |
| |-
| |
| | bgcolor="LightGray"|1.
| |
| |bgcolor= "Turquoise"|B
| |
| |-
| |
| |colspan="1" style="text-align:center; background:Red"| [[ESC #Classification of Recommendations|Class III]]
| |
| |colspan="0.5" style="text-align:center; background:LightGray"|[[ESC #Level of Evidence|'''Level of Evidence''']]
| |
| |-
| |
| | bgcolor="LightGray"|1.
| |
| |bgcolor= "Turquoise"|B
| |
| |}
| |
|
| |
|
| == Case Studies == | | == Case Studies == |
| Line 163: |
Line 56: |
| [[Category:Up-To-Date cardiology]] | | [[Category:Up-To-Date cardiology]] |
| [[Category:Disease]] | | [[Category:Disease]] |
| | |
| | ==References== |
